Bladder cancer: FDA approves novel treatment enfortumab vedotin-ejfv


  • Deepa Koli
  • Oncology drug update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The FDA has approved enfortumab vedotin-ejfv (Nectin-4-directed antibody and microtubule inhibitor conjugate) for adult patients with locally advanced/metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.
  • Further trial is required to confirm the clinical benefits.

Why this matters

  • Patients who fail on initial treatment have limited options.
  • "Antibody-drug conjugates are strategic tools in the targeted treatment of cancer," Richard Pazdur, director of the FDA’s Oncology Center of Excellence, said in a statement. "These conjugates combine the ability of monoclonal antibodies to target specific receptors on cancer cells and then deliver a drug to the cancer cell."

Key highlights

  • Approval was based on a study of 125 patients with locally advanced/metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy.
  • The overall response rate was 44% (complete response, 12%; partial response, 32%).
  • The median duration of response was 7.6 months.
  • Most common adverse events were fatigue, peripheral neuropathy, decreased appetite, rash, alopecia, nausea, altered taste, diarrhea, dry eye, pruritus, and dry skin.

For Prescribing Information, click  here